Tumor Necrosis Correlates with PD-L1 and PD-1 Expression in Lung Adenocarcinoma

被引：0

作者：

Moldvay, J. ^{[1
]}

Teglasi, V. ^{[2
]}

Pipek, O. ^{[3
]}

Rojko, L. ^{[4
]}

Glasz, T. ^{[2
]}

Vagvolgyi, A. ^{[4
]}

Kovalszky, I. ^{[2
]}

Gyulai, M. ^{[5
]}

Lohinai, Z. ^{[4
]}

Raso, E. ^{[2
]}

Timar, J. ^{[2
]}

Dome, B. ^{[4
]}

Szallasi, Z. ^{[2
]}

Reiniger, L. ^{[2
]}

机构：

[1] Natl Koranyi Inst Pulmonol, Dept Tumor Biol, Budapest, Hungary

[2] Semmelweis Univ, Budapest, Hungary

[3] Elte, Budapest, Hungary

[4] Natl Koranyi Inst Pulmonol, Budapest, Hungary

[5] Cty Hosp Pulmonol, Torokbalint, Hungary

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

PD-L1; lepidic growth pattern; tumor necrosis;

D O I：

10.1016/j.jtho.2019.08.1053

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.09-24

引用

页码：S505 / S505

页数：1

共 50 条

[21] The Positive Expression of PD-L1/PD-1 in Gastroenteropancreatic Neuroendocrine Neoplasias Correlates with Prognosis
Yinying, W.
Chuying, W.
NEUROENDOCRINOLOGY, 2017, 105 : 141 - 141
[22] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Lipson, Evan J.
Lilo, Mohammed T.
Ogurtsova, Aleksandra
Esandrio, Jessica
Xu, Haiying
Brothers, Patricia
Schollenberger, Megan
Sharfman, William H.
Taube, Janis M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[23] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
Saito, Hiroaki
Kono, Yusuke
Murakami, Yuki
Shishido, Yuji
Kuroda, Hirohiko
Matsunaga, Tomoyuki
Fukumoto, Yoji
Osaki, Tomohiro
Ashida, Keigo
Fujiwara, Yoshiyuki
ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
[24] PD-L1/PD-1 and arsenic lung tumorigenesis.
Xu, Wenhua
Chen, Gang
CANCER RESEARCH, 2021, 81 (13)
[25] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, Jinhua
Chen, Zichao
Li, Yaqun
Zhao, Wenjie
Wu, JiBiao
Zhang, Zhen
FRONTIERS IN PHARMACOLOGY, 2021, 12
[26] PD-1/PD-L1 axis in cancer cells contributes to cellular EMT in lung adenocarcinoma
Su, Wen-Pin
Chang, Li-Chan
Yan, Jing-Jou
Su, Wu-Chou
CANCER RESEARCH, 2019, 79 (13)
[27] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Janning, Melanie
Kobus, Franca
Babayan, Anna
Wikman, Harriet
Velthaus, Janna-Lisa
Bergmann, Sonja
Schatz, Stefanie
Falk, Markus
Berger, Lars-Arne
Boettcher, Lisa-Marie
Paesler, Sarina
Gorges, Tobias M.
O'Flaherty, Linda
Hille, Claudia
Joosse, Simon A.
Simon, Ronald
Tiemann, Markus
Bokemeyer, Carsten
Reck, Martin
Riethdorf, Sabine
Pantel, Klaus
Loges, Sonja
CANCERS, 2019, 11 (06):
[28] PD-1/PD-L1 inhibitors
Sunshine, Joel
Taube, Janis M.
CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
[29] PD-1/PD-L1 in disease
Kuol, Nyanbol
Stojanovska, Lily
Nurgali, Kulmira
Apostolopoulos, Vasso
IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
[30] PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
Cao, Jinfeng
Brouwer, Niels J.
Richards, Kate E.
Marinkovic, Marina
van Duinen, Sjoerd
Hurkmans, Daan
Verdegaal, Els M. E.
Jordanova, Ekaterina S.
Jager, Martine J.
ONCOTARGET, 2017, 8 (33) : 54722 - 54734

← 1 2 3 4 5 →